Germany I want Wacker Biotech to be recognised for its scientific expertise, speed, collaboration, and flexibility The expectations placed on today’s CDMOs extend far beyond manufacturing capacity, demanding scientific expertise, integrated development capabilities and resilient supply networks capable of supporting increasingly complex therapies. Wacker Biotech has responded by building a distinctive…
Korea James Park discusses Lotte Biologics’ strategy to establish itself as a global CDMO through dual manufacturing hubs in the US and Korea, advanced biologics and ADC capabilities, and a strong service-oriented culture. He outlines the company’s expansion plans, technological differentiation, and support for Korea’s emerging biotech ecosystem, while reflecting on…
Taiwan Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through the state-backed TSMC (Taiwan Semiconductor Manufacturing Company), the island functions as the world’s foundry, manufacturing the advanced chips designed by…
Taiwan With US-China geopolitical tensions pushing multinational pharma to seek manufacturing bases outside China, does Taiwan’s CDMO sector offer a compelling alternative? Recent US policy moves could reshape the global pharmaceutical supply chain. Most significantly, by blocking any company that receives federal funding or government contracts from using ‘high-risk’ Chinese…
Taiwan Lee-Cheng (LC) Liu, CEO of EirGenix, reflects on the evolution of Taiwan’s biotech sector and the company’s role within it as both a biologics CDMO and biosimilar developer. Liu discusses government-backed manufacturing initiatives, shifting global supply chains, and how regulatory changes are reshaping the biosimilar landscape. He also outlines EirGenix’s…
Taiwan As global pharmaceutical companies diversify their manufacturing networks and seek trusted development partners, Taiwan’s CDMO sector is moving into sharper international focus. Drawing on decades of experience building ScinoPharm into a globally recognised API supplier, Jo Shen discusses the evolution of Taiwan’s life sciences ecosystem, the creation of the Taiwan…
China In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft for a new BIOSECURE Act. While the final version of the law, signed by President Donald Trump in December…
Taiwan Dr Chen-Yu Cheng, founder and chairman at Formosa Laboratories & Pharmaceuticals, is leading a strategic transition from generic API manufacturing toward high- value CDMO services and innovative drug development. By leveraging proprietary nanotechnology and antibody-drug conjugate platforms, the group is diversifying into injectables and considering the US market. Dr Cheng…
USA After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable supply. As CTO of Transcenta, he and his team have advanced continuous bioprocessing, delivering dramatic productivity improvements over traditional batch…
France The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics, vaccines, active pharmaceutical ingredients (APIs), and medtech. It offers potential investors a fully integrated value chain from early-stage R&D through…
Taiwan Dr Cyrus Yang, CEO of Taiwan Bio Therapeutics, outlines how he transformed the company – founded in 2014 with proprietary MSC‑expansion technology – into a global innovator in cell and gene therapy. Under his leadership, Taiwan Bio advanced MSC and Tregmodalities, built infrastructure via its TDM model, and aims to make immunosuppressants…
USA Orla Cloak, CEO of Minaris, explains how the organisation. was formed by integrating Minaris Regenerative Medicine, a dedicated cell and gene therapy (CGT) CDMO, and WuXi Advanced Therapies, which brought both CGT manufacturing and established GMP biosafety testing capabilities. Today, Minaris operates under private equity as two complementary businesses: Minaris…
See our Cookie Privacy Policy Here
